ICT 140
Alternative Names: ICT-140Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator ImmunoCellular Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 30 Dec 2022 ICT 140 is still in preclinical development for Ovarian cancer in USA (Parenteral)
- 28 May 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)